A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
This study is to characterize the safety, tolerability, pharmacokinetics (PK),
immunogenicity, pharmacodynamics (PD) and anti-tumor activity of AK112, a PD-1/VEGF
bispecific antibody, as a single agent in adult subjects with advanced solid tumor
malignancies. This trial is a two parts, phase I/II study. All patients are advanced solid
tumor, Eastern Cooperative Oncology Group (ECOG) performance status 0-1. Part one is dose
escalation phase,part two is dose expansion phase. The primary end point is safety. Secondary
end points are objective response rate,progression-free survival and overall survival per
RECIST1.1.